Antigen Presenting Cell Vaccine Development Service
Antigen Presenting Cell (APC) vaccine development represents a cutting-edge approach to cancer immunotherapy, utilizing specialized immune cells to prime the immune system and initiate potent anti-cancer immune responses. At Alfa Cytology, we specialize in developing APC-based cancer vaccines that harness the body's own immune cells to target and eliminate cancer cells effectively.
Overview of Antigen Presenting Cell Vaccine
APC-based vaccines utilize APCs, typically dendritic cells, to present cancer-specific antigens to the immune system. The process begins with the isolation of APCs from the patient's blood or bone marrow. These APCs are then loaded with cancer-specific antigens, either by pulsing them with tumor antigens or through genetic modification techniques. Once activated and loaded with antigens, APCs are reintroduced into the patient's body, where they stimulate a targeted immune response against cancer cells.
Fig.1 Antigen targeting strategies for different APC populations. (Melgoza-González, E. A., et al., 2023)
Antigen-presenting cell (APC) vaccines are the second largest subclass of cancer vaccines, after peptide vaccines. DC vaccine is the classic antigen-presenting cell and the subject of most clinical studies. Other than the brain, the most common indications for DC vaccines include blood, lung, skin (melanoma) and breast cancers.
Examples of current therapeutic studies for DC/APC vaccines
| Product Name |
Clinic Phase |
Indication |
Antigen material |
Antigen type |
Antigens |
Route |
Combination therapy |
Specific combination |
Extra details |
| AV-GBM-1 |
3 |
Glioblastoma |
Lysate (autologous) |
Lysate |
N/A |
SC |
Chemotherapy, cytokine |
Temozolomide, GM-CSF |
N/A |
| DCaT-RNA |
3 |
Uveal melanoma |
TTRNA (autologous) |
Lysate |
N/A |
IV |
None |
N/A |
N/A |
| DC/AML |
2 |
AML (in remission) |
Tumor fusion (autologous) |
Tumor fusion |
N/A |
Unspecified |
None |
N/A |
N/A |
| DC1 |
1 |
Breast cancer |
Unknown |
TAA |
HER2 |
IN |
Chemotherapy, surgery |
TCHP |
N/A |
| N/A |
2 |
Liver cancer, colorectal cancer |
Peptide |
Neoantigen |
N/A |
ID |
Antibody-ICB |
Nivolumab |
N/A |
| alpha-DC1/TBVA |
2 |
Clear cell renal carcinoma |
Peptide |
TAA |
Tumor blood vessel antigens |
ID |
Chemotherapy, surgery |
Cabozantinib |
Alpha type 1-polarized DC |
| N/A |
1 |
Melanoma (metastatic) |
Lysate, peptide |
Lysate, TAA |
NY-ESO-1 |
ID |
Cell therapy, cytokine |
T cells (TIL), IL-2 |
N/A |
| AST-VAC2 |
1 |
NSCLC |
Unknown |
TAA |
hTERT |
ID |
None |
N/A |
Allogeneic, ESC-derived DC |
Our Services
Our APC-based cancer vaccine development service is tailored to deliver personalized treatment solutions that activate and enhance the body's immune response against cancer. By utilizing specialized antigen-presenting cells, we ensure precise targeting of cancer-specific antigens, offering a highly targeted and effective immunotherapy approach.
- DC vaccines
- Monocyte vaccines
- Artificial APCs
- B cell–based vaccine
- Human umbilical vein endothelial cells
Workflow of Our Service
Antigen Selection
Antigen Loading
APC Activation
Vaccine Administration
Immune Response Monitoring
Evaluation of Therapeutic Efficacy
Optimization and Iteration
The Advantages of Our Gene Therapy Development Service
Precision Targeting
APC-based vaccines enable precise targeting of cancer-specific antigens, minimizing off-target effects and maximizing treatment efficacy.
Personalized Immunotherapy
By utilizing the patient's own immune cells, APC-based vaccines offer personalized and targeted immunotherapy tailored to the individual's cancer profile.
Potent Immune Activation
Antigen-presenting cells are highly efficient in stimulating potent and long-lasting immune responses against cancer cells, providing durable protection against cancer recurrence.
Experience the transformative potential of APC-based cancer vaccines in cancer treatment with Alfa Cytology. Our multidisciplinary team of experts is committed to advancing the field of personalized immunotherapy and delivering innovative treatment solutions that make a meaningful difference in patients' lives. Contact us today to learn more about our Antigen Presenting Cell vaccine development service and discover how we can help you combat cancer with precision and efficacy.
Reference
-
Melgoza-González, E. A., et al.; (2023). Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine. Frontiers in Immunology, 14, 1080238.
! For research use only.
Related Services
